The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.
Additionally, patients administered with PBF-680 showed statistically significant improvement compared to placebo treated patients in most of the secondary endpoints evaluated, including FEV1 AUC on day 15 and the Asthma Control Questionnaire.
Remarkably, PBF-680 treatment caused a robust decrease in eosinophil counts at day 15, which recover to normal values two weeks later.
No serious adverse events were reported in the trial, demonstrating once again the very good safety and tolerability profile of the compound.
La mejor actitud que podemos adoptar es la de trat...
El equipo de investigadores observó cambios en el...
El gen AtCDF3 promueve una mayor producción de az...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Curapath se complace en reconocer el importante avance logrado por Mac...
